Next Article in Journal
Antioxidant and Free Radical Scavenging Capacity of Seed and Shell Essential Oils Extracted from Abrus precatorius (L)
Next Article in Special Issue
Friedreich’s Ataxia: A Neuronal Point of View on the Oxidative Stress Hypothesis
Previous Article in Journal
Antioxidant Activity and Thermal Stability of Oleuropein and Related Phenolic Compounds of Olive Leaf Extract after Separation and Concentration by Salting-Out-Assisted Cloud Point Extraction
Previous Article in Special Issue
Antioxidant Activity of Grapevine Leaf Extracts against Oxidative Stress Induced by Carbon Tetrachloride in Cerebral Cortex, Hippocampus and Cerebellum of Rats
Open AccessReview

Melatonin Therapy in Patients with Alzheimer’s Disease

1
Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina, Buenos Aires 1007, Argentina
2
Centro de Neuropsiquiatría y Neurología de la Conducta, Hospital de Clínicas "José de San Martín", Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina
*
Author to whom correspondence should be addressed.
Antioxidants 2014, 3(2), 245-277; https://doi.org/10.3390/antiox3020245
Received: 8 February 2014 / Revised: 9 March 2014 / Accepted: 17 March 2014 / Published: 10 April 2014
(This article belongs to the Special Issue Oxidative Stress and Neurodegenerative Diseases)
Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD. View Full-Text
Keywords: melatonin; Alzheimer’s disease; neurodegeneration; free radicals; oxidative stress; aging; mild cognitive impairment; melatonin analogs melatonin; Alzheimer’s disease; neurodegeneration; free radicals; oxidative stress; aging; mild cognitive impairment; melatonin analogs
Show Figures

Graphical abstract

MDPI and ACS Style

Cardinali, D.P.; Vigo, D.E.; Olivar, N.; Vidal, M.F.; Brusco, L.I. Melatonin Therapy in Patients with Alzheimer’s Disease. Antioxidants 2014, 3, 245-277.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop